Projects per year
Early decision making of batch vs continuous and which type of crystalliser to select is a key decision point. Four different lab-scale (100’s ml) crystallisers were investigated and compared for multistage, multi--zone, antisolvent-cooling crystallisation of a proprietary anticancer active pharmaceutical ingredient (API). The seeding load (1&5%), antisolvent addition rate and residence times were fixed across all four platforms based on fixed process conditions. This work aims to enable decision making earlier in the development cycle by understanding how batch reactors compare to their continuous counterparts. Investigate how to run small scale "batch" experiments to replicate continuous performance. Develop a comparative basis to select an ideal crystalliser for early stage development with less material than is currently possible.
|Number of pages||1|
|Publication status||Published - 21 Oct 2020|
|Event||CMAC Annual Open Day - Virtual event, Glasgow, United Kingdom|
Duration: 21 Oct 2020 → 22 Oct 2020
|Conference||CMAC Annual Open Day|
|Period||21/10/20 → 22/10/20|
- batch crystalising
- continuous crystallisation
FingerprintDive into the research topics of 'Multistage, multi-zones antisolvent-cooling crystallisation of a proprietary API: experimental comparison of effect of geometry and hydrodynamics in four batch crystallisers'. Together they form a unique fingerprint.
- 1 Finished